The role of artificial intelligence in health insurance systems for managing multimorbidity (communicable and non-communicable diseases) in older adults: A scoping review
2026· BIO Web of Conferences· 0 citations· 13 references
TL;DR
Robust governance, explainable AI (XAI), and effective human monitoring are essential for safeguarding vulnerable elderly populations and improving health equity.
Abstract
The aging population is fueling geriatric multimorbidity—the confluence of communicable and noncommunicable diseases—which is putting strain on health insurance ecosystems. In accordance with the Sustainable Development Goals (SDGs 3 and 10), this assessment looks into the use of Artificial Intelligence (AI) to manage these problems and ensure fair treatment. Following PRISMA-ScR guidelines, a systematic search of important databases (PubMed, Scopus, Web of Science, and EMBASE) was conducted for literature published between 2016 and 2026. Out of 1,245 initial screened data, 15 relevant studies were discovered and examined. AI drives three major innovations: (1) ensemble machine learning algorithms (e.g., XGBoost) outperform traditional actuarial models in predicting claim costs; (2) clinical AI optimizes polypharmacy and speeds up early infectious disease detection; and (3) automated machine learning architectures provide robust claim fraud detection. However, algorithmic bias and opaque usage management strategies for care denial cause severe ethical concerns. While AI increases financial and clinical efficiency, its application must extend beyond cost containment. Robust governance, explainable AI (XAI), and effective human monitoring are essential for safeguarding vulnerable elderly populations and improving health equity.
The growing availability of electronic health records (EHRs) has accelerated the use of artificial intelligence (AI) and machine learning (ML) in public health. Yet, how well these methods work in low- and middle-income countries (LMICs), remains poorly understood. This review synthesises studies on ML-based prediction...
Joe Phiri, Aaron Zimba, C. Njovu et al.· Discover Artificial Intellig...· 0 citations
This systematic review examines contemporary machine learning methods and explainable AI procedures engaged prediction of heart diseases and classification and applies explainability AI heart disease prediction models that will ease the process and also make the upcoming system with better progress and more trustworthy...
R. Jain, Sachin H. Patel· International journal of com...· 0 citations
Type 2 diabetes mellitus (T2DM) affects hundreds of millions of people worldwide, and nearly half of all cases remain undiagnosed. This technical review, conducted under conducted under the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and structured around the Population, Inter...
Kattia Orozco-Romero, Jonas Pariona-Torres, Jose Cornejo· Bioengineering· 0 citations
Artificial intelligence (AI) is increasingly used to convert heterogeneous clinical data into actionable predictions across chronic disease pathways, yet the maturity and clinical role of AI differ substantially among diabetes, cardiovascular disease (CVD), and cancer. This structured comparative evidence synthesis eva...
Reshmi Gopalakrishnan· Natural Resources for Human...· 0 citations
Cardiovascular diseases (CVDs) are a public health issue in many countries and the primary cause of disease burden worldwide, leading to the increasing cost of health care. Artificial intelligence (AI) and machine learning (ML) tools offer promising solutions for predicting health care costs for cardiovascular pa...
Alireza Banaye Yazdipour, Mohammad Amiri-Ara, Parisa Mehdizadeh· BMC Medical Informatics and...· 0 citations
INTRODUCTION
Health services are struggling to cope with the growing numbers of people coming with skin lesions they are worried could be cancer. Using artificial intelligence (AI) to assist in the triage process is one potential approach. Deep Ensemble for the Recognition of Melanoma (DERM) is one such AI device which...
Javad Javan, Z. Zhelev, B. Grigore et al.· PharmacoEconomics - Open· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.